Clorox (CLX) Valuation Check As Earnings Beat And Recovery Efforts Draw Fresh Investor Attention

Like
Comment
Favorite

Clorox (CLX) Valuation Check As Earnings Beat And Recovery Efforts Draw Fresh Investor Attention

Simply Wall St.01-09 02:43

Clorox (CLX) is back in focus as investors look ahead to its upcoming fiscal Q2 2026 earnings, after the company previously topped Wall Street profit expectations despite revenue pressures and ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2602397559?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/5211000-choice2-main-header/1585186858909","is_english":true,"pubTime":"2026-01-09 02:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602397559","market":"hk","top_or_hot":-1,"title":"Clorox (CLX) Valuation Check As Earnings Beat And Recovery Efforts Draw Fresh Investor Attention","media":"Simply Wall St.","content":"<div>\n<p>Clorox (CLX) is back in focus as investors look ahead to its upcoming fiscal Q2 2026 earnings, after the company previously topped Wall Street profit expectations despite revenue pressures and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/household/nyse-clx/clorox/news/clorox-clx-valuation-check-as-earnings-beat-and-recovery-eff\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clorox (CLX) Valuation Check As Earnings Beat And Recovery Efforts Draw Fresh Investor Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClorox (CLX) Valuation Check As Earnings Beat And Recovery Efforts Draw Fresh Investor Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-09 02:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/household/nyse-clx/clorox/news/clorox-clx-valuation-check-as-earnings-beat-and-recovery-eff><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Clorox (CLX) is back in focus as investors look ahead to its upcoming fiscal Q2 2026 earnings, after the company previously topped Wall Street profit expectations despite revenue pressures and ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/household/nyse-clx/clorox/news/clorox-clx-valuation-check-as-earnings-beat-and-recovery-eff\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLX","symbol_name":"高乐氏","start_time":0,"source_url":"https://simplywall.st/stocks/us/household/nyse-clx/clorox/news/clorox-clx-valuation-check-as-earnings-beat-and-recovery-eff","article_id":"2602397559","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/5211000-choice2-main-header/1585186858909"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/household/nyse-clx/clorox/news/clorox-clx-valuation-check-as-earnings-beat-and-recovery-eff","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2602397559","pubTimestamp":1767897799,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Clorox (CLX) is back in focus as investors look ahead to its upcoming fiscal Q2 2026 earnings, after the company previously topped Wall Street profit expectations despite revenue pressures and operational disruptions.\nSee our latest analysis for Clorox.\nAt a share price of $101.76, Clorox has seen short term momentum soften after earlier gains, with a 90 day share price return of a 15.2% decline alongside a 1 year total shareholder return loss of 34.27%, as investors weigh its earnings beat,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CLX":"高乐氏","CLX.AU":"CTI LOGISTICS LTD"},"translate_title":"随着盈利超出预期和复苏努力引起投资者新的关注，高乐氏(CLX)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLX.AU":1.5,"CLX":1.5},"content_text":"Clorox (CLX) is back in focus as investors look ahead to its upcoming fiscal Q2 2026 earnings, after the company previously topped Wall Street profit expectations despite revenue pressures and operational disruptions. See our latest analysis for Clorox. At a share price of $101.76, Clorox has seen short term momentum soften after earlier gains, with a 90 day share price return of a 15.2% decline alongside a 1 year total shareholder return loss of 34.27%, as investors weigh its earnings beat, ongoing cost normalization, and recent analyst rating and price target adjustments. If you are reassessing your defensives after Clorox’s recent swings, it can be useful to compare across other consumer names using healthcare stocks as a starting point. With shares down sharply over the past year yet trading below the average analyst price target and some models suggesting a wide intrinsic discount, you have to ask yourself: is this consumer staple on sale, or is the market already baking in whatever growth comes next? AdvertisementMost Popular Narrative Narrative: 16.9% Undervalued Compared with the last close at US$101.76, the most followed narrative sees Clorox’s fair value materially higher, built on a detailed earnings recovery story.  The full-scale implementation of a modern ERP system is expected to drive long-term operational efficiencies, improving supply chain visibility, speeding innovation cycles, and reducing structural costs, which should support margin expansion and sustained earnings growth once short-term transition noise normalizes.  Read the complete narrative. Curious what kind of revenue profile, margin rebuild, and future P/E these assumptions need to hold together? The narrative leans on precise earnings and cash flow paths that are anything but generic. The details sit in the timelines, the mix shift, and the terminal multiple. That is where the fair value really takes shape. Result: Fair Value of $122.41 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on Clorox avoiding prolonged category softness and on managing intense price competition in areas like Glad and cat litter that could squeeze margins. Find out about the key risks to this Clorox narrative. Another View: Market Multiple Sends A Mixed Signal There is a twist when you step away from narratives and look at simple pricing. Clorox trades on a P/E of 15.7x, almost in line with its fair ratio of 15.6x, yet below both its global Household Products peers at 16.7x and a peer set at 21.9x. That combination suggests the stock is not obviously cheap or expensive on this metric alone, but the gap to peers hints at either a safety margin or a quality discount. The question for you is whether that gap closes through better execution or stays in place for longer. See what the numbers say about this price — find out in our valuation breakdown. NYSE:CLX P/E Ratio as at Jan 2026 Build Your Own Clorox Narrative If you look at this and think the story should read differently, or simply prefer to shape your own view from the data, you can build a fresh thesis in just a few minutes with Do it your way. A great starting point for your Clorox research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? If Clorox is raising fresh questions for you, this is the moment to widen your watchlist and pressure test your thinking against other types of opportunities.  Spot potential high risk high reward setups by checking out these 3545 penny stocks with strong financials that already clear some basic financial quality filters. Position ahead of major tech shifts by scanning these 27 AI penny stocks that are tied to artificial intelligence themes across different parts of the market. Zero in on value focused ideas using these 879 undervalued stocks based on cash flows to see which companies currently screen as priced below their estimated cash flow potential.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}